GlassScriptPhysician profile
Adarsh K Gupta
NPI 1720150204
$8,277.44
in general payments reported to CMS, 2019-2025
25 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $359 · 2021: $1,338 · 2022: $1,326 · 2023: $1,405 · 2024: $1,487 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,045 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,045.07 |
| Education | $161.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,435.93 | 2019-2025 | Spravato |
| Harmony Biosciences LLC | $1,084.92 | 2020-2025 | Wakix |
| Abbvie INC. | $882.97 | 2021-2025 | |
| Axsome Therapeutics, INC. | $880.67 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $656.32 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $449.16 | 2022-2025 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $411.46 | 2019-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $351.42 | 2021-2025 | Caplyta |
| Lundbeck LLC | $332.01 | 2019-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $292.36 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $292.33 | 2022-2025 | Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $240.43 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $212.53 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $163.43 | 2022-2025 | Azstarys |
| Alfasigma USA, INC. | $94.45 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $87.59 | 2022-2025 | Loreev Xr |
| Allergan, INC. | $87.50 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $70.53 | 2025 | Cobenfy |
| Inspire Medical Systems, INC. | $54.48 | 2025 | Inspire |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $51.11 | 2025 | Rejoyn |
| Bausch Health US, LLC | $35.18 | 2019 | |
| Novo Nordisk INC | $34.41 | 2023 | Saxenda, Wegovy |
| Eisai INC. | $31.40 | 2021 | |
| Vanda Pharmaceuticals INC. | $24.60 | 2024 | Fanapt |
| Idorsia Pharmaceuticals US INC | $20.25 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adarsh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.